Caplin Point Laboratories Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/5n8qf4lka0w676kne6gi7xfd.pdf

Key Takeaways


The Pipeline Build: Facilities, Filings & ANDAs

C. C. Paarthipan: "That's why I said the next two years is not going to be the bedrock of our future business. The bedrock actually is in the form of work in progress. Once it starts rectifying, you will see something different."

US & Regulated Markets: Early Traction, Long Runway


LatAm & Larger Geographies: The 24-Month Growth Thesis

C. C. Paarthipan: "After two years, yes, it's definitely possible, if the markets are not commoditized totally, because that's one thing you know. And then if the rulers don't come with some policy like what has happened today to some other industry, that's the reason today, probably individual excellence has to outplace or outscore actually the politics."

Business Model Moat: Private Market Control & Vertical Integration

C. C. Paarthipan: "If you look at other companies, most of the companies which are doing well, you will not be able to find one company which has made money in a nonregulated market in generic. That's because no company has to take a risk actually, it is risk to go to these types of smaller geographies."

Capital Allocation: Cash Pile, No Payout, Waiting for the Right Deal

Vivek Partheeban: "On paper, it was excellent numbers. In fact, the size of the acquisition was a significant one, and we were open to it. But once you started peeling away the layers and understanding the next 5 years, it just didn't seem like what we expected it to be."

Working Capital & Geopolitical Friction


Guidance & Commitments

CommitmentSpecificsTimeline
COL injectables on streamINR 90 crore injection project goes liveProbably by December (current FY)
ANDA count targetReach 45–46 ANDAs once 5 more acquisitions closeComing few weeks
Prefilled syringe filingsFile almost all 11 advanced-stage productsBy next financial year
Mexico product filingsFile 80–90 products in MexicoWithin next 12 months
CSU own-label launchesLaunch another 15 products under own labelNext financial year
Oncology API facility completionFacility completedNext year
Larger LatAm market entryBusiness in Mexico, Colombia, Chile beginsQ4 of next year
20–25% revenue growthGrowth rate accelerates to 20–25%24 months from call date
40% operating marginAchieve 40% margin, conditional on market and policy environmentAfter two years

Key Metrics

MetricQ2 FY26
Operating revenue growth11% YoY
Total income growth12% YoY
H1 revenue₹1,098 cr, exceeding full-year FY21 revenue of ₹1,085 cr
Other income₹14.18 cr, primarily from deployment of incremental cash
EBITDA growth18.2% YoY, above revenue growth
EBITDA marginNot stated as a percentage; Opex as a percentage of total revenue was 24.8% vs 25.6% last year
PBT₹385.5 cr, +19.4% YoY from ₹322.8 cr; PBT margin 35.1% vs 32.9% last year
PAT₹311 cr, +21.6% YoY; PAT margin 28.3% vs 26.1% last year
Net worth₹3,159 cr, crossing ₹3,000 cr mark
Liquid assets₹2,358 cr, exceeding annual revenue
Cash and cash equivalents₹1,334 cr, vs ₹1,180 cr as of March 2025
Capitalization during H1₹48 cr, with additional ₹2 cr of depreciation
WIP (Work in Progress)₹174 cr, of which Caplin One Lab injection projects ~₹90 cr
Receivables117 days, vs 118 days as of March 2025
Cash flow from operations (H1)₹254 cr, vs ₹186 cr in corresponding period last year
Free cash flow after capex (H1)₹160 cr, vs ₹109 cr in corresponding period last year
Caplin Steriles (CSL + CSU) consolidated PBT₹20.2 cr, vs ₹17.13 cr last year
Caplin Steriles EBITDA₹37.2 cr
ANDAs (acquired + in process)4 acquired, 5 more in process; expected to reach 45–46 total
CSU products launched24 within first 12 months; targeting 15 more next financial year
Mexico product filings35+ filed, 20 approvals; pipeline of 80–90 to be filed within 12 months
Chile product licenses125
Products at advanced development stages11, planned for filing by next financial year
Inventory at customer locations and in transit67% of total inventory
Private market share of business70–75%